Adrienne Graves takes root on board to help Akorn grow
This article was originally published in Scrip
Executive Summary
Niche generic pharmaceutical company Akorn has appointed Dr Adrienne Graves to its board of directors. Dr Graves is an industry leader in ophthalmology, having served as president and CEO of Santen, the US subsidiary of Santen Pharmaceutical from 2002-2010. She currently serves on the boards of TearLab Corporation, Encore Vision, the American Academy of Opthalmology Foundation and the Pan-American Committee for the Brown University Medical School, plus the advisory board of Amach Capital Partners.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.